‘Next generation’ leukaemia drug approved on NHS

NICE backs NHS use of Autolus' leukaemia CAR-T

Hundreds of people with an aggressive leukaemia will be able to access a CAR-T therapy developed by UK biotech Autolus after a NICE recommendation.

NHS gives green light to 'life-saving' leukaemia treatment with 77% remission rate

The NHS has given the green light to a groundbreaking immunotherapy that could transform treatment for a rare and aggressive blood cancer. The therapy, known as obe-cel or Aucatzyl, targets B-cell acute lymphoblastic leukaemia and represents a major advance in cancer care.This innovative treatment harnesses the body's own defences by reprogramming cells to hunt down and destroy cancer. It's been created by Autolus, a company that emerged from Un…

‘Next generation’ leukaemia drug approved on NHS

Immunotherapy treatment modifies cells to attack blood cancer and could assist patients with limited options

NHS to use ‘next generation’ treatment to cure leukaemia

The therapy only needs to be given once

‘Next generation’ treatment to cure leukaemia given NHS approval

‘The biggest thing it offers is hope,’ says patient involved in clinical trial which cured cancer in significant portion of leukaemia sufferers

‘Next generation’ treatment to cure leukaemia given NHS approval

The therapy was developed by Autolus, a University College London spinout company. A “next generation” immunotherapy treatment that has the potential to cure leukaemia has been given NHS approval. Obe-cel is a type of CAR T-cell therapy developed in the UK and works by genetically modifying cells to enable the body’s own immune system to recognise and attack cancer. The therapy, which only needs to be given once in a lifetime, was developed by A…